a biotechnology company, which engages in marketing and selling multi-cancer screening and detection test that uses patented cancer differentiation analysis, or CDA, technology.
Industry Biotechnology
A.I.dvisor indicates that over the last year, FRES has been closely correlated with CLNN. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if FRES jumps, then CLNN could also see price increases.
| Ticker / NAME | Correlation To FRES | 1D Price Change % | ||
|---|---|---|---|---|
| FRES | 100% | -10.54% | ||
| CLNN - FRES | 81% Closely correlated | -7.23% | ||
| RIGL - FRES | 78% Closely correlated | -3.61% | ||
| DARE - FRES | 77% Closely correlated | +0.31% | ||
| HOOK - FRES | 76% Closely correlated | -1.84% | ||
| AZTR - FRES | 73% Closely correlated | -2.71% | ||
More | ||||
| Ticker / NAME | Correlation To FRES | 1D Price Change % |
|---|---|---|
| FRES | 100% | -10.54% |
| FRES (8 stocks) | 17% Poorly correlated | -6.00% |
| Medical Specialties (433 stocks) | 10% Poorly correlated | -1.94% |